Anders Nelson

Anders Nelson

Auto-generated profile, based on publicly available information

Anders Nelson

AstraZeneca 2 Bioscience, Oncology R&D Waltham, Massachusetts

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 January 2021 in The Journal of Immunology
Verified
Journal Article
Open access
PDF file
XLXiaji Liu
Xiaji Liu
JZJingyuan Zhang
Jingyuan Zhang
AZAngela C. Zeigler
Angela C. Zeigler
ANAnders R. Nelson
Anders R. Nelson
Merry L LindseyMerry L Lindsey
Merry L Lindsey
JSJeffrey J. Saucerman
Jeffrey J. Saucerman
Macrophages are subject to a wide range of cytokine and pathogen signals in vivo, which contribute to differential activation and modulation of inflammation. Understanding the response to multiple, often-conflicting cues that macrophages experience requires a network perspective. In this study, we integrate data from literature curation and mRNA expression profiles obtained from wild type C57/BL6J mice macrophages to develop a large-scale computational model of the macrophage signaling network. In response to stimulation across all pairs of nine cytokine inputs, the model predicted activation along the classic M1–M2 polarization axis but also a second axis of macrophage activation that distinguishes unstimulated macrophages from a mixed phenotype induced by conflicting cues. Along this second axis, combinations of conflicting stimuli, IL-4 with LPS, IFN-γ, IFN-β, or TNF-α, produced mutual inhibition of several signaling pathways, e.g., NF-κB and STAT6, but also mutual activation of the PI3K signaling module. In response to combined IFN-γ and IL-4, the model predicted genes whose expression was mutually inhibited, e.g., iNOS or Nos2 and Arg1, or mutually enhanced, e.g., Il4rα and Socs1, validated by independent experimental data. Knockdown simulations further predicted network mechanisms underlying functional cross-talk, such as mutual STAT3/STAT6-mediated enhancement of Il4rα expression. In summary, the computational model predicts that network cross-talk mediates a broadened spectrum of macrophage activation in response to mixed pro- and anti-inflammatory cytokine cues, making it useful for modeling in vivo scenarios.

6 July 2021 in Journal of the American Heart Association
Verified
Journal Article
Open access
PDF file
NCNicholas W. Chavkin
Nicholas W. Chavkin
SSSoichi Sano
Soichi Sano
YWYing Wang
Ying Wang
KOKosei Oshima
Kosei Oshima
HOHayato Ogawa
Hayato Ogawa
KWKenneth Walsh
Kenneth Walsh
Background: A hallmark of heart failure is cardiac fibrosis, which results from the injury‐induced differentiation response of resident fibroblasts to myofibroblasts that deposit extracellular matrix. During myofibroblast differentiation, fibroblasts progress through polarization stages of early proinflammation, intermediate proliferation, and late maturation, but the regulators of this progression are poorly understood. Planar cell polarity receptors, receptor tyrosine kinase–like orphan receptor 1 and 2 (Ror1/2), can function to promote cell differentiation and transformation. In this study, we investigated the role of the Ror1/2 in a model of heart failure with emphasis on myofibroblast differentiation. Methods and Results: The role of Ror1/2 during cardiac myofibroblast differentiation was studied in cell culture models of primary murine cardiac fibroblast activation and in knockout mouse models that underwent transverse aortic constriction surgery to induce cardiac injury by pressure overload. Expression of Ror1 and Ror2 were robustly and exclusively induced in fibroblasts in hearts after transverse aortic constriction surgery, and both were rapidly upregulated after early activation of primary murine cardiac fibroblasts in culture. Cultured fibroblasts isolated from Ror1/2 knockout mice displayed a proinflammatory phenotype indicative of impaired myofibroblast differentiation. Although the combined ablation of Ror1/2 in mice did not result in a detectable baseline phenotype, transverse aortic constriction surgery led to the death of all mice by day 6 that was associated with myocardial hyperinflammation and vascular leakage. Conclusions: Together, these results show that Ror1/2 are essential for the progression of myofibroblast differentiation and for the adaptive remodeling of the heart in response to pressure overload.

26 March 2026 in Molecular Cancer Therapeutics
Verified
Journal Article
Open access
PDF file
ABAzadeh C. Bashi
Azadeh C. Bashi
TPTheresa A. Proia
Theresa A. Proia
MLMandy Lawson
Mandy Lawson
ANAnders Nelson
Anders Nelson
LILucy Ireland
Lucy Ireland
SBSimon T. Barry
Simon T. Barry
Trastuzumab deruxtecan (T-DXd), an antibody–drug conjugate composed of an anti-HER2 antibody and a cytotoxic topoisomerase I inhibitor, is approved for the treatment of HER2-positive (HER2+) and HER2-low breast cancer as well as HER2-high gastric and HER2-mutant lung cancer tumors. The AKT inhibitor capivasertib is approved for the treatment of HER2− estrogen receptor–positive breast cancer with alterations in PIK3CA, PTEN, and AKT-1. The potential for the combination of T-DXd with AKT inhibition to enhance antitumor activity was explored in HER2+ or HER2-low preclinical models. In vitro, combination activity was observed in both HER2-high– and HER2-low–expressing breast cancer as well as in gastric, endometrial, and ovarian models, irrespective of HER2 expression level or PI3K–AKT status pathway alterations. The T-DXd–capivasertib combination effect translated in vivo with increased antitumor benefit in HER2-expressing, PI3K–AKT pathway–altered tumor xenografts when compared with the combination of trastuzumab and capivasertib. In cell lines sensitive to the combination, combining T-DXd with capivasertib targeted complimentary pathways which resulted in disruption of the cell cycle and increased cell death. These results suggest that T-DXd combined with capivasertib has the potential to be active in HER2+ as well as HER2-low tumors independent of PI3K pathway alteration status.

2 July 2026
Verified
Other
Open access
ABAzadeh C. Bashi
Azadeh C. Bashi
TPTheresa A. Proia
Theresa A. Proia
MLMandy Lawson
Mandy Lawson
ANAnders Nelson
Anders Nelson
LILucy Ireland
Lucy Ireland
SBSimon T. Barry
Simon T. Barry
Supplementary Table 2. Antibody details

2 July 2026
Verified
Other
Open access
ABAzadeh C. Bashi
Azadeh C. Bashi
TPTheresa A. Proia
Theresa A. Proia
MLMandy Lawson
Mandy Lawson
ANAnders Nelson
Anders Nelson
LILucy Ireland
Lucy Ireland
SBSimon T. Barry
Simon T. Barry
Supplementary Figure 8. Active cell cycle distribution analysis of KPL4, EFM19 and KPL4 cells treated with T-DXd or capivasertib monotherapy, or the combination

2 July 2026
Verified
Other
Open access
ABAzadeh C. Bashi
Azadeh C. Bashi
TPTheresa A. Proia
Theresa A. Proia
MLMandy Lawson
Mandy Lawson
ANAnders Nelson
Anders Nelson
LILucy Ireland
Lucy Ireland
SBSimon T. Barry
Simon T. Barry
Supplementary Figure 11. Individual animals plots for breast, ovarian and endometrial xenograft models treated with T-DXd, capivasertib or the combination.